BioArctic AB’s partner Eisai will hold several presentations at the Alzheimer’s Association International Conference to be held in Denver, Colorado and virtually from July 26 to 30, 2021.
STOCKHOLM, July 21, 2021 /PRNewswire/ -- BioArctic AB‘s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai will hold several presentations at the Alzheimer’s Association International Conference (AAIC) to be held in Denver, Colorado and virtually from July 26 to 30, 2021. The presentations will include the latest data of the investigational anti-amyloid beta (Aβ) protofibril selective antibody lecanemab (BAN2401) for which the FDA has granted Breakthrough Therapy designation.
The presentations regarding lecanemab include oral presentations about the preliminary assessment of the clinical effect of lecanemab following 18 months of treatment in the open-label extension of the Phase 2b proof of concept study (201 study) in subjects with early Alzheimer’s disease and preliminary screening and baseline characteristics of the Phase 3 clinical study, AHEAD 3-45, for preclinical (asymptomatic) Alzheimer’s disease.
Eisai oral presentations
| Asset in Development/Topic Number | Topic/Planned Date and Time |
| (U.S. Mountain Daylight Time) | |
| Lecanemab | AHEAD 3-45 Study: Preliminary Screening and Baseline Characteristics from a Placebo-Controlled, Double-Blind Study Evaluating Lecanemab Treatment in Participants with Preclinical Alzheimer’s Disease and Elevated (A45 Trial) and Intermediate (A3 Trial) Amyloid |
| Oral presentation No.53143 | Oral presentation: July 29 (Thu) 8:00 AM-9:15 AM |
| Lecanemab | Preliminary Assessment of the Clinical Effects of Lecanemab Following 18 Months of Treatment in the Open Label Extension of the Phase 2 Proof of Concept Study, BAN2401-G000-201, in Subjects with Early Alzheimer’s Disease |
| Oral presentation No.57780 | Oral presentation: July 29 (Thu) 1:00 PM-2:15 PM |
Eisai poster presentations
| Asset in Development/Topic Number | Topic/Planned Date and Time |
| (U.S. Mountain Daylight Time) | |
| Lecanemab | Baseline Characteristics for Clarity AD: A Phase 3 Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study Evaluating Lecanemab (BAN2401) |
| Poster No.54331 | On demand |
| Lecanemab | Plasma Aβ42:40 Ratio Tracks with Changes in Brain Amyloid PET SUVr in the Core and Open Label Extension of the Phase 2 Proof of Concept Study BAN2401-G000-201 Following Treatment with Lecanemab in Subjects with Early Alzheimer’s Disease |
| Poster No.57760 | On demand |
This release discusses investigational uses of an agent in development and is not intended to convey conclusions about efficacy or safety. There is no guarantee that any investigational uses of such product will successfully complete clinical development or gain health authority approval.
For further information, please contact:
Gunilla Osswald, CEO, BioArctic AB
E-mail: gunilla.osswald@bioarctic.se
Phone: +46 8 695 69 30
Oskar Bosson, Vice President Communications and Investor Relations, BioArctic AB
E-mail: oskar.bosson@bioarctic.se
Phone: +46 70 410 71 80
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
| Curtain raiser AAIC |
View original content:https://www.prnewswire.com/news-releases/latest-data-on-lecanemab-to-be-presented-at-alzheimers-association-international-conference-aaic-301338299.html
SOURCE BioArctic
Company Codes: Stockholm:BIOAB, ISIN:SE0010323311, RICS:BIOAB.ST, Bloomberg:BIOAB@SS, RICS:BIOAB.ST
